LRP3 (low-density lipoprotein receptor-related protein 3) is a member of the LDL receptor family, a receptor superfamily involved in endocytosis and cell-surface signaling in the nervous system.[1] Compared with better-studied paralogs such as LRP1, LRP3 remains under-characterized; however, emerging data suggest it can modulate amyloid precursor protein (APP)-related biology and therefore may influence Alzheimer's disease-relevant pathways.[2]
| Property | Value |
|---|---|
| Gene Symbol | LRP3 |
| Full Name | Low Density Lipoprotein Receptor-Related Protein 3 |
| Chromosomal Location | 19q13.31 |
| NCBI Gene ID | 4037 |
| Ensembl ID | ENSG00000186603 |
| UniProt ID | O75074 |
LRP-family proteins typically combine extracellular ligand-binding domains with transmembrane and cytoplasmic motifs that support ligand uptake, trafficking, and downstream signaling.[1:1] Within this framework, LRP3 is hypothesized to participate in membrane-protein turnover and lipoprotein-associated cargo handling, although its endogenous ligand repertoire in human brain tissue remains incompletely defined.[1:2][2:1]
What is currently supported:
Recent mechanistic work indicates that LRP3 can reduce APP levels, linking this receptor to amyloidogenic risk architecture.[2:4] This does not yet establish LRP3 as a primary causal Alzheimer's gene, but it supports a model where LRP3 acts as a pathway modifier of APP homeostasis.
Because LDL receptor family signaling intersects with lipid transport and synaptic receptor turnover, LRP3 may also influence neuronal resilience under metabolic and inflammatory stress states that accompany neurodegeneration.[1:4][3][4]
Evidence for LRP3 in neurodegeneration is currently early-stage:
Potential translational directions include:
At present, there is no approved LRP3-directed therapy for neurodegenerative disease.
Herz J, Strickland DK. LRP: a multifunctional scavenger and signaling receptor. J Clin Invest. 2001. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Camporesi E, Nilsson N, Brinkmalm A, et al. The apolipoprotein receptor LRP3 compromises APP levels. Alzheimers Res Ther. 2021. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Kanekiyo T, Xu H, Bu G. ApoE and Aβ in Alzheimer's disease: accidental encounters or partners?. Neuron. 2014. ↩︎ ↩︎
Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013. ↩︎